OncoMed Trying To Regroup After Cancer Stem Cell Pipeline Failures

After the Phase II failure of anti-cancer stem cell antibody tarextumab in small-cell lung cancer, another in a string of failures, execs highlight potential of other pipeline assets, including immuno-oncology targets.